| 1.41 -0.15 (-9.62%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.28 |
1-year : | 2.67 |
| Resists | First : | 1.95 |
Second : | 2.28 |
| Pivot price | 1.66 |
|||
| Supports | First : | 1.4 |
Second : | 1.17 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.71 |
| MA(100) : | 1.95 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 12.1 |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 4.05 | Low : | 1.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GDTC ] has closed below the lower bollinger band by 1.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.65 | 1.65 - 1.65 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.39 - 1.41 | 1.41 - 1.43 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Mon, 08 Dec 2025
CytoMed Therapeutics (NASDAQ: GDTC) plans first-in-human gamma delta T cell trial in Malaysia - Stock Titan
Mon, 08 Dec 2025
CytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer Trial - TipRanks
Mon, 08 Dec 2025
CytoMed Therapeutics (NASDAQ: GDTC) to run first-in-human Malaysia trial of donor-derived γδ T cells - Stock Titan
Tue, 18 Nov 2025
CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India - TipRanks
Tue, 18 Nov 2025
CytoMed Therapeutics Completes Acquisition of Allogeneic Gamma Delta T Cell Technology from TC BioPharm - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 67.3 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | -452.2 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | 101 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -5.64 |
| PEG Ratio | 0 |
| Price to Book value | 2.93 |
| Price to Sales | 22.66 |
| Price to Cash Flow | -5.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|